Welcome to PanGenX . Our mission is to help people get the most effective medical treatments for their specific individual needs.
Dan is well known for his strategic insight and consulting in personalized medicine, diagnostics and health IT. Prior to PanGenX, Dan consulted at Third Rock Ventures, with focus on evaluation and establishment of novel therapeutic companies. As a Scientia co-founder, he led numerous strategic projects in technology assessment, in- and out-licensing, commercialization, financing and partnering, and life cycle management.
Dan is a serial entrepreneur and founding management team member of several successful companies with deals exceeding $700 million. These include CombinatoRx and Glenveigh Pharma, where ground-breaking orphan indication efforts resulted in a repositioned biologic for preeclampsia. Dan also led the successful financing and eventual sale of the company.
Dan’s healthcare experiences and interactions with thought leaders formed his idea around a unique opportunity to address a critical unmet need affecting patient healthcare outcomes. By unifying relavant, siloed, genetic research and clinical data through semantic linking, novel, evidence-based interpretations could be applied to improve therapeutic development and implementation . This recognition and passion, also shared by founding investors, bioinformaticians, semantics web and genetic experts, became the catalyst for the formation and funding of PanGenX.
Paul is responsible for the development of PanGenX’s software platform including cloud-based services, data integration, semantic web, analytics and visualization technologies. Paul is a serial entrepreneur who has co-founded a number of startups, non-profits, and open source projects based on technologies including semantic web, identity management, privacy, security, electronic communications, and electronic publishing.
Prior to joining PanGenX Paul co-founded Azigo.com a consumer internet service that gives people more control over their relationships with brands. Prior to Azigo he was involved in user-centric identity management. During this period he started the Higgins Personal Data Service project at the Eclipse Foundation, and chaired the Information Card Foundation whose board members included Google, Microsoft, Verizon, Oracle and several others. He consulted for several years to the Office of the Secretary of Defense on command and control technology.
In 2000 Paul was the president of Bitstream/Pageflex, a public company in the electronic publishing space that he co-founded with VC and angel funding in 1985. Prior to this he co-founded Lightspeed Computers a computer aided design company acquired by DuPont in 1985. Paul has a BSEE degree from MIT and was a research assistant at the MIT Media Lab.
David specializes in interim executive management, IPOs, turnarounds, strategic analysis, and mergers & acquisitions. Prior to joining PanGenX, David, over the previous 18 years, has operated his own consulting firm providing executive services to various life science companies. Previous clients include Stromedix, where, as CFO, David helped the company complete its $500+ Million acquisition by Biogen. As CFO of Glycofi, David was involved in its $400 Million acquisition by Merck. David was Vice President of Finance at Alnylam Pharmaceuticals, Inc., where he led the company to a successful IPO. He also served as Vice President Finance and Administration at Infinity Pharmaceuticals, and as Corporate Controller at Millennium Pharmaceuticals. Prior to running his own consulting firm, David was an auditor at KPMG for more than four years.
David received his bachelor’s degree in accounting from the University of Minnesota, and his MBA from Bentley College. He is also a certified public accountant.
Tom is a seasoned life science industry executive. He has an extensive peer-reviewed scientific publication list and has maintained premier collaborative research efforts with both academia and industry throughout his career. He led new diagnostic assay development at Ventana and HTG. At Medtronic, he managed global biotechnology opportunity identification and assessment. His efforts resulting in groundbreaking treatment advances by combining the company’s novel delivery technologies with approved therapeutics.
Prior to Medtronic, Tom was vice president of business development at Lynx Therapeutics, Inc. (later Solexa and eventually acquired by Illumina Inc.). There, he developed and applied next generation DNA sequencing technologies for high speed, whole genome analysis. Tom has also served in various technology and business development roles at Millennium Pharmaceuticals, Corning Advanced Life Science Products, and LabSeek Scientific Collaborative. Through the course of his career, Tom has brokered numerous deals with large therapeutic companies and academic institutions and served as a business and technology consultant for academic and commercial organizations around the world.
Tom received a B.S. degree in chemistry from MIT and a Ph.D. in Genetics from Harvard University, and completed postdoctoral training in developmental biology at Princeton University.
Seema brings over 18 years of deep healthcare knowledge and extensive strategic marketing experience to PanGenX. Her spectrum of biotech marketing experience ranges through all phases from pre-clinical/clinical development to pre-launch planning and launch execution to post-marketing brand management.
Prior to Pangenx, Seema held product management and leadership roles in new product development and brand marketing at Genzyme® and Sanofi®. At Genzyme and Sanofi, Seema achieved a successful track record of new product launches including the development of world-wide marketing campaigns through her sophisticated brand development process, her ability to convert complex data to tangible, executable plans, and her collaborative approach to mobilize cross functional, global teams. Seema leverages her holistic, patient-centric perspective to guide her marketing strategies and tactics to support sales growth.In addition to her work at PanGenX, Seema serves on the Board of Overseers for Children’s Hospital of Boston, the Strategic Advisory Board for The Partnership Inc., and is also a peer reviewer for Massachusetts Life Sciences Center.
Seema received her MBA from MIT Sloan School of Management and her Bachelor of Science degree in physical therapy from Northeastern University. Seema was also named Boston Business Journal’s 40 under 40 in 2011.
With more than 15 years of experience in managing biomedical multi-disciplinary research programs, both in academic and biotech industry settings, Dr. Irina Agoulnik oversees company operations, and is involved in strategizing PanGenX product development. Irina utilizes her extensive scientific training and management skills to provide leadership in implementing the company’s mission, vision, strategy, and long-term planning. Her focus is on maximizing the company’s business objectives and building a high performance culture of engagement and focused initiative.
Prior to joining PanGenX, for eight years Irina worked with two institutions affiliated with Harvard Medical School: Dana Farber Cancer Institute and Brigham and Women’s Hospital. As Director of Operations for the $24M, five-year, NIH-funded Systems-based Consortium for Organ Design and Engineering (BWH) initiative, Irina worked closely with program directors, consortium team leaders, External Advisory Board members and NIH program officers, to implement interdisciplinary research consortium (IRC) strategy, and participated in the National Evaluation of the NIH IRC program.
At Millennium Pharmaceuticals (now Takeda Pharmaceuticals), Irina contributed to the successful achievement of company milestones in drug target identification and validation, by employing strategic plans for process improvement, including quality of gene expression data ($8M in savings), and by participating in microarray technology transfer to partner companies ($2.6M in revenues).
Irina holds a Ph.D. in Biology, an M.S. in Physics, and a diploma in computer programming. She has co-authored a patent based on her doctoral study, and her work at Princeton University resulted in several co-authored publications. Irina actively supports cancer research through affiliations with several charitable organizations, including Pan Mass Challenge and United Way’s Caring Club. She served as a conference program chair for Social Network Analysis TIG, American Evaluation Association.